company background image
6996 logo

Antengene SEHK:6996 Stock Report

Last Price

HK$0.56

Market Cap

HK$411.7m

7D

-17.6%

1Y

-58.5%

Updated

25 Jul, 2024

Data

Company Financials +

Antengene Corporation Limited

SEHK:6996 Stock Report

Market Cap: HK$411.7m

6996 Stock Overview

A biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally.

6996 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Antengene Corporation Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Antengene
Historical stock prices
Current Share PriceHK$0.56
52 Week HighHK$2.25
52 Week LowHK$0.60
Beta0.88
11 Month Change-30.86%
3 Month Change-39.78%
1 Year Change-58.52%
33 Year Change-96.17%
5 Year Changen/a
Change since IPO-96.94%

Recent News & Updates

Recent updates

Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

Jan 09
Revenues Tell The Story For Antengene Corporation Limited (HKG:6996)

The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Sep 20
The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26%

Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

Apr 03
Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates

We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Feb 19
We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Nov 05
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

Jun 28
We Think Antengene (HKG:6996) Can Afford To Drive Business Growth

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Nov 18
We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Aug 17
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

Apr 29
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth

What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Feb 22
What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares?

Shareholder Returns

6996HK PharmaceuticalsHK Market
7D-17.6%-2.7%-1.6%
1Y-58.5%-8.3%-2.8%

Return vs Industry: 6996 underperformed the Hong Kong Pharmaceuticals industry which returned -8.3% over the past year.

Return vs Market: 6996 underperformed the Hong Kong Market which returned -2.8% over the past year.

Price Volatility

Is 6996's price volatile compared to industry and market?
6996 volatility
6996 Average Weekly Movement7.1%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement6.7%
10% most volatile stocks in HK Market14.4%
10% least volatile stocks in HK Market3.7%

Stable Share Price: 6996's share price has been volatile over the past 3 months.

Volatility Over Time: 6996's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017201Jay Meiwww.antengene.com

Antengene Corporation Limited, a biopharmaceutical company, engages in the development of novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients in Mainland China, Singapore, Australia, Hong Kong, Macau, and Taiwan. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR kinase inhibitor for the treatment of cervical cancer and other advanced solid tumors.

Antengene Corporation Limited Fundamentals Summary

How do Antengene's earnings and revenue compare to its market cap?
6996 fundamental statistics
Market capHK$411.68m
Earnings (TTM)-HK$625.46m
Revenue (TTM)HK$72.43m

5.2x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6996 income statement (TTM)
RevenueCN¥67.31m
Cost of RevenueCN¥12.29m
Gross ProfitCN¥55.01m
Other ExpensesCN¥636.20m
Earnings-CN¥581.18m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.86
Gross Margin81.74%
Net Profit Margin-863.51%
Debt/Equity Ratio15.7%

How did 6996 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.